The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease.

ELISA MRM antibodies assay development biomarkers diabetic kidney disease immunoaffinity multiplex targeted mass spectrometry

Journal

Proteomes
ISSN: 2227-7382
Titre abrégé: Proteomes
Pays: Switzerland
ID NLM: 101621966

Informations de publication

Date de publication:
28 Oct 2020
Historique:
received: 30 09 2020
revised: 22 10 2020
accepted: 27 10 2020
entrez: 31 10 2020
pubmed: 1 11 2020
medline: 1 11 2020
Statut: epublish

Résumé

PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In parallel, and facilitating current clinical laboratory workflows, a standard ELISA was also developed to measure each protein. The performance characteristics of the two technology platforms were compared using a cohort of 100 samples, with PromarkerD test scores demonstrating a high correlation (R = 0.97). These technologies illustrate the potential for large scale, high throughput clinical applications of proteomics now and into the future.

Identifiants

pubmed: 33126588
pii: proteomes8040031
doi: 10.3390/proteomes8040031
pmc: PMC7709118
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Diabetes Complications. 2019 Dec;33(12):107406
pubmed: 31669066
Expert Rev Proteomics. 2020 Apr;17(4):257-273
pubmed: 32427033
Proteomics. 2019 May;19(10):e1700448
pubmed: 30353665
Clin Transl Med. 2014 Mar 29;3(1):7
pubmed: 24679154
Crit Rev Clin Lab Sci. 2020 Jun 19;:1-12
pubmed: 32552254
Clin Proteomics. 2020 Oct 20;17:37
pubmed: 33093819
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1371-9
pubmed: 26175542
Immunochemistry. 1971 Sep;8(9):871-4
pubmed: 5135623
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11
pubmed: 26970494
Acta Pharmacol Sin. 2018 Jul;39(7):1068-1072
pubmed: 29645001
Nat Rev Cancer. 2017 Mar;17(3):199-204
pubmed: 28154374
Clin Proteomics. 2013 Oct 02;10(1):13
pubmed: 24088261
Int J Epidemiol. 2013 Apr;42(2):412-21
pubmed: 22544845
FEBS Lett. 1971 Jun 24;15(3):232-236
pubmed: 11945853
Diabetes Care. 2017 Nov;40(11):1548-1555
pubmed: 28851702
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Oncologist. 2019 Jun;24(6):e251-e259
pubmed: 30139835
EuPA Open Proteom. 2017 Jan 05;14:1-10
pubmed: 29900119

Auteurs

Scott Bringans (S)

Proteomics International, Perth, WA 6009, Australia.

Kirsten Peters (K)

Proteomics International, Perth, WA 6009, Australia.

Tammy Casey (T)

Proteomics International, Perth, WA 6009, Australia.

Jason Ito (J)

Proteomics International, Perth, WA 6009, Australia.

Richard Lipscombe (R)

Proteomics International, Perth, WA 6009, Australia.

Classifications MeSH